Navigation Links
Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio™(*)) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity
Date:10/5/2011

PARIS, Oct. 5, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today the publication of the pivotal Phase III TEMSO study with investigational once-daily oral medication teriflunomide in The New England Journal of Medicine (NEJM).  Results showed that teriflunomide at the 14mg dosage significantly reduced the annual relapse rate, reduced disability progressions and improved several magnetic resonance imaging (MRI) measures of disease activity, including new or worsening brain lesions.  Teriflunomide has a well-characterized safety profile, with a similar proportion of trial participants reporting adverse events compared to placebo.

"The TEMSO data demonstrate the effect of teriflunomide in terms of reducing relapse rates, disability progression and Magnetic Resonance Imaging (MRI) lesions," said Dr. Paul O'Connor, Director of the MS Clinic at St Michael's Hospital, Toronto, Canada and principal investigator in the TEMSO study.  "These results, sustained over two years, provide clinically meaningful data for teriflunomide."

The two-year TEMSO (TEriflunomide Multiple Sclerosis Oral) trial involved 1,088 people with relapsing forms of MS from 126 centers across 21 countries. TEMSO is the first study from a broad clinical development program that includes more than 4,000 trial participants in 36 countries and is one of the largest and broadest clinical programs of any oral MS agent under development, with five Phase III clinical trials either completed or underway.

"The publication of the teriflunomide results in the New England Journal of Medicine is an exciting milestone as we continue the development of our product," said Dr. Elias Zerhouni, President, Global Research & Development, Sanofi. "As we continue our commitment t
'/>"/>

SOURCE Sanofi; Genzyme
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger
2. Positive Phase III Data on Bayers Investigational Drug Radium-223 Chloride Show Significant Increase in Overall Survival
3. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
4. Bayer to Present New Data Evaluating Investigational Oncology Compounds at 2011 ECCO-ESMO Congress
5. Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
6. FDA Grants Fast Track Designation to Bayers Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
7. CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
8. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
9. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
10. Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Associations 71st Annual Scientific Sessions
11. Morphotek, Inc. Announces That Two Investigational Drugs Have Received Orphan Drug Designations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 Paragon 28, Inc . ... of its foot plating system that supplants the Normed ... TM R3CON PLATING SYSTEM greatly enhances the product ... & Mini-Monster TM Screw Systems and Preserve TM ... interchangeable subsystems, the GORILLA TM R3CON SYSTEM offers ...
(Date:9/22/2014)... , Sept. 22, 2014 The western ... stage. It is largely a replacement market with ... The mergers, acquisitions and partnerships are redefining competitive ... This research service provides details about revenue forecasts, ... pricing trends across the country. The changing landscape ...
(Date:9/22/2014)... September 22, 2014 ... has announced the addition of the  "Global ... & Industrial) Market - Forecast to 2019" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The global freeze drying market ... and is expected to reach at $2,655.9 ...
Breaking Medicine Technology:Paragon 28, Inc. Launches the GORILLA(TM) R3CON PLATING SYSTEM 2Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3Global Freeze Drying / Lyophilization Equipment (Lab, Pilot, & Industrial) Market - Forecast to 2019 2Global Freeze Drying / Lyophilization Equipment (Lab, Pilot, & Industrial) Market - Forecast to 2019 3
... ANN ARBOR, Mich., Feb. 6, 2012  Adeona Pharmaceuticals, Inc. ... synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious ... Director appointments to strengthen and expand the Company,s leadership, ... of the Adeona Board of Directors since March 2010 ...
... Feb. 6, 2012  EntreMed, Inc. (Nasdaq: ENMD ), ... cancer, announced today that Wei-Wu He, Ph.D has joined the ... Ph.D has joined as a member of the Board of ... Dr. Wei-Wu He is currently the CEO and Chairman of ...
Cached Medicine Technology:Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus 2Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus 3Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus 4Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus 5Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors 2Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors 3Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors 4
(Date:9/23/2014)... September 23, 2014 "Bee Towers” was featured ... reviews and features the latest technology gadgets and services available ... expert, conducted the tech review and shared with ... and fatigue. , Tablet sales rates in the United States ... of Americans now own a tablet. , For consumers ...
(Date:9/23/2014)... Pittsburgh, PA (PRWEB) September 23, 2014 ... only home-use conception assistance device on the market cleared ... prescription in stores and online at http://www.storkotc.com . ... whose dream of having a baby is delayed by ... new first step to optimize their chances to conceive. ...
(Date:9/23/2014)... 2014 AltMed , a ... development and production of medical cannabis has signed ... Cannabis . , The two companies will ... They’ll also pool business development know-how to ... , "We’re deeply impressed with the level of ...
(Date:9/23/2014)... led by researchers from the University of Cambridge has found ... early childhood leaves a ,signature, in the brain. The ... Cerebral Cortex . , The researchers studied 80 adult ... 42 who did not. They found that language delay was ... key regions, including the temporal lobe, insula, ventral basal ganglia, ...
(Date:9/23/2014)... WetKeys Washable Keyboards announces the launch of ... industrial keyboards line. Labeled the ‘Really O’Cool’ ... in heavy-duty industrial computing for the oil and gas ... oil can destroy usability or cause data errors. ... the longevity of computer equipment and can dissolve many ...
Breaking Medicine News(10 mins):Health News:“Bee Towers”, a Floor Standing Tablet Holder by XAR Motion, was Featured on NewsWatch, a National Television Show, This Month 2Health News:First-Ever Conception Assistance Device FDA-Cleared for Home Use Launches U.S. OTC Sales -- The Stork® OTC Delivers Hope to Millions Struggling to Conceive A Child 2Health News:First-Ever Conception Assistance Device FDA-Cleared for Home Use Launches U.S. OTC Sales -- The Stork® OTC Delivers Hope to Millions Struggling to Conceive A Child 3Health News:First-Ever Conception Assistance Device FDA-Cleared for Home Use Launches U.S. OTC Sales -- The Stork® OTC Delivers Hope to Millions Struggling to Conceive A Child 4Health News:Florida Medical Cannabis Leader AltMed Allies With Canada's Vida Cannabis To Build Best-in-Class Expertise 2Health News:Florida Medical Cannabis Leader AltMed Allies With Canada's Vida Cannabis To Build Best-in-Class Expertise 3Health News:Presence or absence of early language delay alters anatomy of the brain in autism 2Health News:WetKeys Announces New Oil Resistant Keyboard for Industrial Computing, Food Processing Plants, Automotive Factories and Machine Shops 2Health News:WetKeys Announces New Oil Resistant Keyboard for Industrial Computing, Food Processing Plants, Automotive Factories and Machine Shops 3Health News:WetKeys Announces New Oil Resistant Keyboard for Industrial Computing, Food Processing Plants, Automotive Factories and Machine Shops 4Health News:WetKeys Announces New Oil Resistant Keyboard for Industrial Computing, Food Processing Plants, Automotive Factories and Machine Shops 5
... increasing day by day. The number of infections a person ... risk of death from heart attack. It is long been ... heart disease.// This has been possible by promoting inflammation within ... so far, have conflicting evidence. ,According to researchers ...
... are affected with depression are more likely to die of ... Dr. Robert M. Carney at Washington University School of Medicine ... tend to have poor heart rate variability (HRV). ,Heart ... to contract, which can affect its ability to handle stress ...
... of patients on long-term non-steroidal anti-inflammatory drug (NSAID) ... infection can substantially reduce the risk of ulcer ... per cent of H.pylori infections and reduced the ... in the control group to 12 per cent ...
... new ray of hope for hearing impairment. A new hearing ... sound quality than a more conventional aid. Doctors say that ... usual kind of hearing aid transmits sound through the eardrum, ... as well as giving the wearer the feeling of talking ...
... reason why people go to the doctor. Antibiotics are worthless ... developed a drug that speeds recovery from the common cold ... pursuit of a cure for decades. The new drug, ... eases cold symptoms within a day and makes a runny ...
... when it comes to dealing with women's health issues. The ... moves to tackle diseases affecting women, including heart disease and ... government have done either too little or nothing at all ... ,Neither the nation nor the states have ...
Cached Medicine News:
Cold light source triple outlet....
Cold light source single outlet....
... 4150S is a state of ... light source with an integrated ... coupler to connect optical fiber ... distinguishes itself from all others ...
The 9300XSP is the brightest light source available. Visualize more clearly, see color more accurately, and work more effectively. Luxtecs xenon lighting delivers bright, white light that is as close...
Medicine Products: